Other Mutations	17 (63.0)	17 (56.7)	34 (59.6)
ASXL1	4 (14.8)	4 (13.3)	8 (14.0)
CEBPA	1 (3.7)	3 (10.0)	4 (7.0)
FLT3	1 (3.7)	6 (20.0)	7 (12.3)
FLT3T	1 (3.7)	1 (3.3)	2 (3.5)
NUP98FUS	2 (7.4)	2 (6.7)	4 (7.0)
RUNX1	5 (18.5)	2 (6.7)	7 (12.3)
SETBP1	0 (0.0)	1 (3.3)	1 (1.8)
TP53	1 (3.7)	1 (3.3)	2 (3.5)
Other	13 (8.1)	14 (46.7)	27 (47.4)
Bone marrow blast (%) at baseline			
Median	52.00	72.00	62.30
Min, Max	2.0, 98.0	5.0, 93.0	2.0, 98.0

[0238]

(3) At the time of data cut off, 81 patients （31 patients in Arm A and 50 patients in Arm B） were enrolled. The median age was 57.1 years (range 20-89), 56.8% were female, and 93.8% had AML. The median number of prior lines of therapy was 3 (range 1 to 9). 23 patients (28.4 %) had prior allogeneic stem cell transplant, 63 patients (77.8%) had prior venetoclax, and 5 patients (6.2%) had received a prior menin inhibitor. Documented MLLr was reported in 42 pts (51.9%) and NPM1m in 20 (24.7%).

[0239]

Example 5: Safety evaluation of the present compound

(1) No DLTs have been observed at any dose level of 40 - 200 mg. Majority of the TEAEs were Grade 1 or Grade 2 and managed with supportive care. No drug-related AE has resulted in permanent treatment discontinuation and no treatment-related deaths were observed in the study. Refer to Table 9 for a tabulation of TEAEs in ≥20% of patients regardless of causality, and Table 10 for a tabulation of all TEAEs related to the present compound in ≥2 patients. Treatment-related QT interval prolongation events were not reported. One case of suspected differentiation syndrome has been reported related to the present compound that occurred in a patient with TP-53 mutation, but no cases of differentiation syndrome have occurred in patients with MLLr or NPM1m.

[Table 9]

Preferred Term	Total (N=43)
Nausea	15 (34.9%)
Vomiting	10 (23.3%)
Fatigue	10 (23.3%)
Hypokalaemia	9 (20.9%)

[Table 10]

Preferred Term*	Total (N=43)
Vomiting	4 (9.3%)
Nausea	3 (7.0%)
Decreased appetite	3 (7.0%)
*One patient experienced differentiation syndrome not included due to cut-off ≥2 patients	